[1]
|
R. J. Simes, “Publication Bias: The Case for an International Registry of Clinical Trials,” Journal of Clinical Oncology, Vol. 4, No. 10, 1986, pp. 1529 1541.
|
[2]
|
K. Dwan., D. G. Altman, J. A. Arnaiz, et al., “Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias,” PLoS One, Vol. 3, No. 8, 2008, e3081. doi:10.1371/journal.pone.0003081
|
[3]
|
S. Hopewell, K. Loudon, M. J. Clarke, A. D. Oxman and K. Dickersin, “Publication Bias in Clinical Trials Due to Statistical Significance or Direction of Trial Results,” Cochrane Database of Systematic Reviews, Vol. 1, 2009, MR000006.
|
[4]
|
K. Rising, P. Bachetti and L. Bero, “Reporting Bias in Drug Trials Submitted to the Food and Drug Administra tion: Review of Publication and Presentation,” PLoS Medicine, Vol. 5, No. 11, 2008, e217.
doi:10.1371/journal.pmed.0050217
|
[5]
|
K. Lee, P. Bachetti and I. Sim, “Publication of Clinical Trials Supporting Successful New Drug Applications: A Literature Analysis,” PLoS Medicine, Vol. 5, No. 9, 2008, e191. doi:10.1371/journal.pmed.0050191
|
[6]
|
C. D. Deangelis, J. M. Drazen, F. A. Frizelle, C. Haug, J. Hoey, R. Horton, S. Kotzin, C. Laine, A. Marusic, A. J. Overbeke, T. V. Schroeder, H. C. Sox and M. B. Van Der Weyden, “Clinical Trial Registration: A Statement from the International Committee of Medical Journal Editors,” Journal of the American Medical Association, Vol. 292, No. 11, 2004, pp. 1363 1364.
doi:10.1001/jama.292.11.1363
|
[7]
|
D. A. Zarin, T. Tse and N. C. Ide, “Trial Registration at ClinicalTrials.gov between May and October 2005,” New England Journal of Medicine, Vol. 353, No. 26, 2005, pp. 2779 2787. doi:10.1056/NEJMsa053234
|
[8]
|
Clinicaltrials.gov, “A Service of the US National Insti tutes of Health,” 2010. http://www.clinicaltrials.gov
|
[9]
|
ISI Web of Knowledge, “Journal Citation Reports,” 2010. http://0 admin apps.isiknowledge.com.impulse.ucdenver.edu/JCR
|
[10]
|
S. S. Vedula, L. Bero, R. W. Scherer and K. Dickersin, “Outcome Reporting in Industry Sponsored Trials of Ga bapentin for Off Label Use,” New England Journal of Medicine, Vol. 361, No. 20, 2009, pp. 1963 1971.
doi:10.1056/NEJMsa0906126
|
[11]
|
S. Mathieu, I. Boutron, D. Moher, D. Altman and P. Ravaud, “Comparison of Registered and Published Pri mary Outcomes in Randomized Controlled Trials,” Jour nal of the American Medical Association, Vol. 302, No. 9, 2009, pp. 977 984. doi:10.1001/jama.2009.1242
|
[12]
|
C. D. Deangelis, J. M. Drazen, F. A. Frizelle, C. Haug, J. Hoey, R. Horton, S. Kotzin, C. Laine, A. Marusic, A. J. Overbeke, T. V. Schroeder, H. C. Sox and M. B. Van Der Weyden, “Is This Clinical Trial Fully Registered? A Statement from the International Committee of Medical Journal Editors,” New England Journal of Medicine, Vol. 352, No. 23, 2005, pp. 2436 2438.
doi:10.1056/NEJMe058127
|
[13]
|
J. S. Ross, G. K. Mulvey, E. M. Hines, S. E. Nissen and H. M. Krumholz, “Trial Publication after Registration in ClinicalTrials.gov: A Cross Sectional Analysis,” PLoS Medicine, Vol. 6, No. 9, 2009, e1000144.
doi:10.1371/journal.pmed.1000144
|
[14]
|
S. Garatini and V. Bertele, “Non Inferiority Trials Are Unethical Because They Disregard Patients’ Interests,” Lancet, Vol. 370, No. 9602, 2007, pp. 1875 1877.
doi:10.1016/S0140 6736(07)61604 3
|